ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 176 filers reported holding ALLOGENE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 4.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25 | -37.5% | 7,986 | 0.0% | 0.00% | – |
| Q2 2023 | $40 | -2.4% | 7,986 | -3.2% | 0.00% | – |
| Q1 2023 | $41 | -35.9% | 8,246 | -19.1% | 0.00% | -100.0% |
| Q4 2022 | $64 | -99.9% | 10,192 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $110,000 | -4.3% | 10,192 | +1.0% | 0.00% | 0.0% |
| Q2 2022 | $115,000 | +35.3% | 10,093 | +7.9% | 0.00% | 0.0% |
| Q1 2022 | $85,000 | -71.7% | 9,350 | -53.6% | 0.00% | 0.0% |
| Q4 2021 | $300,000 | +14.5% | 20,172 | +98.1% | 0.00% | -50.0% |
| Q3 2021 | $262,000 | -7.7% | 10,184 | -6.4% | 0.00% | 0.0% |
| Q2 2021 | $284,000 | +4.8% | 10,875 | +41.7% | 0.00% | -80.0% |
| Q1 2021 | $271,000 | +27.2% | 7,676 | -8.9% | 0.01% | +25.0% |
| Q4 2020 | $213,000 | -32.6% | 8,426 | +0.5% | 0.01% | -42.9% |
| Q3 2020 | $316,000 | -4.8% | 8,380 | +8.0% | 0.01% | -6.7% |
| Q2 2020 | $332,000 | – | 7,762 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VV Manager LLC | 1,798,163 | $76,997,000 | 67.53% |
| Wildcat Capital Management, LLC | 1,515,524 | $64,895,000 | 22.42% |
| TPG Group Holdings (SBS) Advisors, Inc. | 19,716,306 | $844,252,000 | 14.91% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1,279,281 | $54,779,000 | 7.69% |
| Coastal Bridge Advisors, LLC | 463,117 | $19,831,000 | 6.33% |
| DSAM Partners (London) Ltd | 235,098 | $10,067,000 | 2.63% |
| Casdin Capital, LLC | 625,000 | $26,763,000 | 1.58% |
| Alpine Global Management, LLC | 150,000 | $6,423,000 | 1.13% |
| Perceptive Advisors | 1,543,790 | $66,105,000 | 1.07% |
| Avoro Capital Advisors LLC | 1,128,594 | $48,326,000 | 0.96% |